V. M. Radiiodinated chloroquine analog in malignant melanoma, 323*
Boyd, C. M.
See Beierwaltes, W. H.
See Lieberman, L. M.
See Varma, V. J.
Boyd, B. E., Ackerman, S. A., Morrise, J. G. and Huberty, J. P.
**Te Fe(OH)** macroaggregates, 737

Bozzao, L. See Fazio, C.
Bradley, B. R. See DeNardo, G. L.
Brady, L. W.
See Fazio, C.
See Lam, S.

Brandy, J. M. See Henegar, G. C.
Branson, B. M. See Sodd, V. J.
Braverman, L. E. and Foster, A. E.
Coomadin effect on thyroid hormone binding, 511

Briggs, R. C. See Sorenson, J. A.
Brill, A. B., Williams, H., Cook, W., Watts, J. R., Johnston, R. E., Nash, R. and Staab, E. V.
Imaging evaluation with simulated data, 389*

Brin, A. B. See Paton, J.
Brody, K. R. See Spencer, R. P.
Brown, D. W. and Groome, D. S.
Digital computer analysis and display, 389*

Brown, D. W.
See Cleveland, J. D.
See Groome, D. S.

Brown, J. M. See Cliggett, P. A.
Brown, M. F. and Hughes, R.
Combined heart and lung scanning in pericardial effusion, 390*

Brown, W. R. See Wilcox, F. W.
Brownell, G.
See Wilensky, S.
See Petushkov, A. A.

Brunner, P. N., Kann, D. E. and Peterson, R. E.
Lymph node imaging with **Te-S colloid, 390*

Bryant, N. See Crews, M. C.

Buchanan, J. W., Rhodes, B. A. and Wagner, H. N.
**In**-albumin microspheres, 487

Bugby, R. D. See Loken, M. K.
Burdine, J. A., Leegay, R., Ryder, L. and Sonnemaker, R.
The modified Anger scintillation camera, 324*

Burdine, J. A., Waltz, T. A., Matsen, F. A. and Rapp, F.
**In** and **Tc** in experimental cerebral lesions, 290

Burdine, J. A., Werch, A. and Ryder, L.
**In**-gelatin complex for placental localization, 324*

Burdine, J. A. See Sano, R.
Burget, C. L. See O'Mara, R. E.
Burke, G., Halbo, A. and Goldberg, D.
**TcO** cardiac blood-flow studies, 270

Burke, G. and Silverstein, G.
Post-radioiodine myxedema, 325*

Burrows, B. A. See Famelant, M. H.
Burny, C. See Lucis, O. J.
Burstein, S. See Solaric, E.
Bush, F. See Martinez-Villaseñor, D.
Byrd, B. L. See Hayes, R. L.

Byrnes, D. J. See Young, J. D.
Cahill, P. T. See Blau, L. M.

Therapy of progressive malignant exophthalmos with **I**-390*
Cameron, J. R. See Sorenson, J. A.
Cannon, P. J. See Johnson, P. M.
Cantor, R. E., Cohn, E. M., Shapiro, B. and Park, C. H.
Liver scanning with **Tc-S and **Au, 391*

Carey, J. E. See Lieberman, L. M.

Carlson, J. G. and Parrish, G. D.
Joint computer-camera instrument, 325*

Carlton, J. E. See Hayes, R. L.
Carulli, N. See Kailara, S.
Casaret, G. See Rubin, P.
Case, L. See Remenchik, A. P.
Cassen, B.
Nonfocused collimator for 3-D scanning, 391*

Castle, J. N. See Cavaleri, R. R.

Castronovo, F. P., Reha, R. C. and Wagner, H. N.
**In**-Ba-EDTA infusion system, 242

Cavaleri, R. R., Castle, J. N. and Searle, G. L.
Free-thyroxine in serum, 565

Cavaleri, R. R. See Searle, G. L.

Cejas, C. See Fischer, D. S.
Cervantes, L. See Eberstadt, P. L.

Charles, N. D. TSH and **I** uptake in Graves' disease, 246

Charles, N. D.
Stereocintigaphy of brain and thyroid, 326*

Charles, N. D.
Bone scans with **Sr and **Sr, 491

Charkes, N. D.
Dosimetry of **I**, 752

Charleston, D. B. See Porter, J. W.

Chaudhuri, T. K. and Spence, R. P.
Dual labeling of erythrocytes with **Fe and **Fe, 122

Chaudhuri, T. K., Winchell, H. S.
and Lawrence, J. H.
Platelet aggregation in determining therapy, 392*

Cheng, H. F., Peterson, R. E. and Evans, T. C.
*Se-selenomethionine incorporation in lymphocytes, 63
Cheng, H. F. and Peterson, R. E.
Metabolic fate of radiolabeled lymphocytes, 326*

Chernelech, M., Fawwaz, R., Sargent, T. and Winchell, H. S.
Colonic absorption of *Fe in dogs, 392*

Chin, F. K. See Kennedy, J. C.

Chisholm, D. J. See Young, J. D.

Chodos, R. B., Streiten, D. H. P., Doisy, R. J., Rekant, S., Dallos, T. and Fellerman, H. *Cr* absorption in elderly and diabetic subjects, 393*

Christensen, E. E. See Bonte, F. J.

Christie, J. H. and MacIntyre, W. J.
Computer analysis of thyroid scans, 393*

Christie, J. H. and MacIntyre, W. J.
Response of collimators to a line source, 394*

Christopherson, W. J., Bergeron, D. A. and Verdon, T. A.
Liver scans with **Tc-colloid, 327*

Christopherson, W. J. and Verdon, T. A.
Liver scans with **Tc-MAA, 394*

Chu, F. See Greenberg, E.

Cieocio, S. S. See Farrer, P. A.

Clawser, S. Book review, 609

Clayton, G. D.
See Berson-Morth, M.
See Fink, S.

Cleveland, J. D., Genton, E., Hellman, H. N., Walton, B. and Brown, D. W.
Simplified method for platelet survival, 395*

Cleveland, J. D., Wiesenberg, A.
L. M. and Manfield, T. P.
Multi-crystal brain scanner, 456*

Clevenger, M. See Gowsitz, F. A.

Clifford, G. O. See Bettigole, R. E.

Cliggett, P. A. and Brown, J. M.
Assay of radioactive materials, 612

Cohen, M. B.
Desk-top digital computer, 327*

Cohen, M. B. and Spolter, L.
Stability of **Tc-S colloid, 395*

Cohen, T. D. See Sanders, T. P.

Cohn, E. M. See Cantor, R. E.

Cohn, H. J. and Stolzer, M. H.
Tissue vascularity in brain scans, 553

Coiner, D. and Walsh, J. R.
Plasma level of *Co-vitamin B, 457*

Cole, R. E. See Kennedy, J. C.

Collins, P. A. See McCarty, D. J.

Colombetti, L. G. and Goodwin, D. A.
**Ga-labeled macroaggregates for lung imaging, 328*

Colombetti, L. G. and Goodwin, D. A.
Chemistry of **Ga-EDTA complex, 396*

Colombetti, L. G., Goodwin, D. A. and Hermanson, R.
**In** for liver and spleen, 597

Colombetti, L. G., Goodwin, D. A. and Hinkley, R. L.
Preparation of sterile radiopharmaceuticals, 633

Colombetti, L. G. See Goodwin, D. A.

Comas, F. V. See Vodopich, H.

Constabales, W. C. See Bell, E. G.

Constantinescu, C., Kostamis, P., Sfantouris, J. and Malamos, B.
Metabolic studies of **Yb, 396*

Constantinescu, C. See Kostamis, P.
Cook, W. See Brill, A. B.
Cook, W. E. See Patton, J.

Cooper, J. F. and Stern, H. S.
Sterile **Tc-albumin "kit," 328*

Coppler, M.
See Franco, J.
See Kowalski, B.

Cornelius, E. A. and Spencer, R. P.
Effects of supralateral irradiation through parabiosis, 328*

Cornelius, E. A. and Spencer, R. P.
Pathologic physiology of graft-versus-host reactions, 396*

Cornell, E. A. See Spencer, R. P.
Cornell, L. H. See Telfer, N.
Corsi, G.
See Boettcher, D.
See Goldschlager, N.
Costello, C. See Holman, B. L.

Counsell, R. E.
See Beierwaltes, W. H.
AUTHORS INDEX

Paulus, J. M., Thompson, K. H., Fillet, G. and Willams, J. Platelet life span and production, 426*

Penkoske, P., Potchen, E. J., Welch, M. J. and Welch, T. J. Chemistry of generator-produced 111In, 646

Penkoske, P. and Welch, T. J.

Perrillo, W. See Touya, E.

Peters, S. M. SeeJump, B. J.

Peterson, R. E.

See Brunner, P. N.

See Cheng, H. F. H.


Phillips, R. A., Lauver, G., Bass, B. G. and Pierson, R. N. Whole-body potassium counting, 426*

Pieklenko, J. R., Paloyan, E., Lathrop, K. A. and Harper, P. V. "Se-selenomethionine uptake in hyperparathyroidism, 363*

Pierson, R. N., Frankel, H. J. and Hitch, J. G. Total-body potassium in hypertension, 427*

Pierson, R. N. and Groce, M. H. Effects of isoproterenol and methacholine on pulmonary blood volume, 427*

Pierson, R. N. and Hitch, J. G.

Reference standard and normal ranges of body K, 364*

Pinston, D. W. See Cragin, M. D.

Pirruccello, R. See Webber, M. M.

Pittman, J. A. See Kontzen, F. N.

Pizer, S. M. See Wilensky, S.

Pizer, S. M. and Vetter, H. G. Processing radioisotope scans, 151

Poe, N. D. Blood flow through the atelectatic lung, 365*

Poe, N. D., Dore, E. K., Swanson, L. A. and Taplin, G. V. Fatal pulmonary embolism, 28

Poe, N. D., Dore, E. K., Wilson, A. F. and Taplin, G. V. Inhalation-perfusion Spar scans, 427*

Poe, R. H. See Mack, J. F.

Poleyn, R. E.

See Gottschalk, A.

See Hoffer, P. B.

See Kranzler, J. K.

See McCarthy, D. J.

Pollard, A. See Koven, I. H.

Polleyevo, M.

See DeGrazia, J. A.

See Fish, M. B.

See O'Reilly, S.

See Weber, P. M.

See Winchell, H. S.

Ponto, R. See Loken, M. K.

Porter, J. W., Harper, P. V. and Charleston, D. B. Efficiencies of Na(Tl) well crystals, 428*

Potchen, E. J.

See Altam, M.

See Archer, E. G.

See Holman, B. L.

See Penkoske, P.

See Studer, R.

See Welch, M.

See Welch, T. J.

See Wochner, D.

Potsaid, M. S. See Eaton, S. B.

Poulose, K. P., Reba, R. C., Deland, F. H. and Wagner, H. N. Liver scanning in preoperative cancer cases, 365*

Poulose, K. P.

See Hurley, P. J.

See Strauss, H. W.

Powell, M. R. See Mangum, J. F.

Prescott, J. H. See Telfer, N.

Preuss, L. E. and Kosnik, L. T. Fat to lean ratio using "Cd, 366*

Preuss, L. E. See Vulpetti, H.

Prince, J. R. See Skinner, S. B.

Pulley, P. E. See Love, W. D.

Qualife, M. A. and Kass, I. Microcirculation defect in chronic obstructive pulmonary disease, 366*

Queen, R. F. See Gibbs, W. D.

Quinn, J. L.

See Crews, M. C.

See Gottschalk, A.

See Westerman, B. R.

Raley, R. See Winchell, H. S.

Ramagopol, E. and DiGiulio, W. Improved method for determining serum thyroxine, 428*

Ramirez, M., Green, M. V. and Vorden, T. A. Eluting "Mo, mTc generators, 461*

Rand, E.

Scintiphotography and ultrasonography for renal masses, 367* "TcO4" in gastric secretory activity, 367*

Bone scanning for metastatic carcinoma, 429*

Ultrasound and imaging of pericardial effusion, 429*

Radionuclide angiography and infrared thermography in carotid occlusive disease, 430*

Echocardiogram and brain imaging, 430*

"P therapy in metastatic prostatic cancer, 430*

Rapid lung scanning, 430*

Rapid pancreas scanning, 430* Pericardial effusion diagnosis, 430* Total-body bone scanning, 431*

Rapp, P. See Burdine, J. A.

Rau, J. See Goldsmith, R. E.

Raynaud, C., Ricard, S., Karam, J. and Kellershorm, C. "Hg" for kidney function, 367*

Razaz, M. A., Botti, R. E. and MacIntyre, W. J. Renogram, effects of hydration and blood flow, 672

Reba, R. C.

See Gastronovo, F. P.

See Guilday, D. L.

See Poulose, K. P.

Reddy, M., Harper, P. V. and Beck, R. N. Figure of merit for imaging systems, 431*

Reddy, M., Harper, P. V.

See Reid, E. L. See Ashkar, F. S.

Rekant, S. See Chodos, R. B.


Rhodes, B. A. and Stern, H. S. "Kt" for mTc labeled albumin microspheres, 368*

Rhodes, B. A. and Wagner, H. N. Lung imaging with mTc-albumin microspheres, 432*

Rhodes, B. A.

See Buchanan, J. W.

See Hurley, P. J.

Rhodes, F. See Antar, M. A.

Rhyme, A. See Maynard, C. D.

Ricard, S. See Raynaud, C.

Rich, C. R. See Murano, R.

Richards, P. and O'Brien, M. J. Rapid determination of "Mo in separated mTcO4, 517

Richards, P. See Atkins, H. L.

Richardson, R. H. See Welch, M. A.

Risberg, J. See Paulson, O. B.

Robinson, A. See Siemsen, J. K.

Robinson, A. M. See Graham, T. P.

Rodda, J. E., Soloway, A. H., Benda, P. and Sweet, W. H. Biological behavior of K"MnO4, 205

Rodriguez, J., MacDonald, N. S. and Taplin, G. V. "In in albumin aggregates for liver and lung, 368*

Roghair, G. See Farrer, P. A.

Rollo, F. D. and Schulz, A. G. Spatial resolution characteristics of scanning systems, 432*

Rood, J. E. See Holmes, R. A.

Romiti, D. W. See Wellman, H. N.

Ronai, P., Winchell, H. S., Anger, H. O. and Lawrence, J. H. Whole-body mFe scanning, 469

Ross, G. S. See Bell, E. G.

Rothschild, E. O. See Weber, D. A.

Rubenfeld, S.

See Gold, F. M.

See Maglione, A.

Rubin, P., Farrer, P. A. and Casserett, G. Radiation arthropathy, 433*

Rubin, P.

See Farrer, P. A.

See Spar, J. L.

Rudd, T. G. See Murano, R.

Rupp, E. M. See Vodopick, H.

Russell, M. E. See Lawrence, C. A.

Ryder, L. Burdine, J. A.

Sachs, C. E. See Farniel, M. H.

Saenger, E. L.

See Mark, J. F.

See Wellman, H. N.

Sagerman, R. H. See Johnson, P. M.

Sakamoto, A. See Kaplan, E.

Salazar, H. E. O. See Callejas, R. F.

Samuels, L. D. and Bass, J. C. "Cr lung scan in idiopathic pulmonary hemosiderosis, 106

Samuels, L. D. and Bass, J. C. "Cr lung scanning in idiopathic pulmonary hemosiderosis, 433*

Samuels, L. D. and Hipple, T. F. Premedication for mTcO4; brain scans, 234

Samuels, L. D. and Stewart, C. Liver scanning for recurrent tumors in children, 433*

Sanders, T. P., Cohen, T. D. and Kuhl, D. E. mTc window setting in an Anger camera, 369*
NaBH₄, method of labeling with ⁹⁹mTc, 443*
structure of heat microaggregated, 414*
⁹⁹mTc, kit for sterile preparation, 328*
⁹⁹mTc labeled micropheres, lung imaging, 432*

**Albumin, macroaggregated**
see Iodine-131, macroaggregated albumin; Technetium-99m

**Albumin, microaggregated**
see Technetium-99m

**Americium-241**
fluorescence detection, cerebral blood flow, 651
rectilinear transmission scanning for bone mineral content, 379*

**Angiography**
cerebral, scintillation camera, ⁹⁹mTcO₄⁻, 354* 
cerebrovascular accidents, ⁹⁹mTcO₄⁻, 401*
comparison with lung scintiphotography, 380*
comparison with scanner and scintillation camera, for brain tumor, 349*

**Angiotensin II**
nitroimmunoassay, 347*

**Antimony-125**
a-1-antitrypsin deficiency, lung scanning, 687
uptake, distribution and retention, in mice, 436*

**Assay**
¹³¹I capsule count variation, effect on thyroid uptake, 461*
radioassay ¹⁹⁷C-hemoglobin, 261
radiopharmaceutical, 147, 558
thyrotropin, 356*
thyroxine, comparison radioisotope and column chromatography methods, 281

**Autofluoroscope**
cerebral blood flow with ⁹⁹mTcO₄⁻, 410*, 501
circulatory dynamics in cerebral vascular disease, 438*
clinical evaluation, 408*
design of dynamic phantoms, 416*
liver imaging, ¹⁹⁷Au colloid, 441*
liver imaging by sequential count subtraction, 439*
lung imaging, 341*
myocardial blood flow with ¹³³Xe, 412*

**Autoradiography**
"hot" thyroid nodules, ¹³¹I and ¹²⁵I, 691
kidney distribution of radionuclides, in rabbits, 362*

**Barium-137m**
EDTA, sustained infusion system, in dogs, 242

**Bicarbonate**
kinetics of CO₂-HCO₃⁻ pool, 382*

**Blood**
exchange in liver failure, 408*
hemoglobin kinetics, in animals, 352*
lymphocyte kinetics in chronic lymphocytic leukemia, 404*
myocardial blood flow with ¹³¹Rb, in dogs, 83

**Blood plasma**
volume measured by ¹³¹In-transferrin space, 383*

**Blood volume**
change in spaceflight, 346*
double tag, ²⁴⁷Cr-RBC and ¹³¹I-albumin, 400*
¹³¹In-gelatin, comparison with ¹³¹I-albumin, 402*
¹³¹In in transferrin, 397*, 442*
prediction, 407*
preparation of ¹³¹In compound in closed system, 318*
pulmonary, effects of isoproterenol and methacholine, 427*
use of total-body hematocrit, 350*

**Board of Nuclear Medicine**
report on negotiations, 55, 663

**Bone**
"Ca kinetics, effects of radiation therapy, 338*
imaging with HEDTA complexes of ⁶⁷Sm, ⁶⁷Er and ⁶⁷Lu, in rabbits, 49
joint, scintiphotography, ⁹⁹mTcO₄⁻, 356*
parathormone and ³¹P therapy, 376*
permissible levels for bone-seekers, 406*
radiation damage from therapy, ¹⁹⁷F imaging, 320*
rectilinear transmission scanning for mineral content, 379*
rectilinear transmission scanning, ⁹⁹mTc point source, 252
spondylitis, ⁶⁷Sr, comparison of analytic procedures, 213
total body, imaging, 431*

**Bone marrow**
erythropoietic, ⁸⁷Fe whole-body scanning, 469
imaging, ⁹⁹mTc-S colloid, in children with thalassemia, 351*
¹³¹I, ⁹⁹mTc microaggregated albumin, 453*
preparation of ¹³¹In colloid in closed system, 318*
post-irradiation RE cell and erythron function, in rabbits, 361*
radiation damage from therapy, imaging with ⁹⁹mTc-S colloid, 320*
⁹⁹mTc-Fe colloid for imaging, in rabbits, 56

**Bone scanning**
comparison ⁶⁷Sr and ⁹⁹mSr, 491
¹⁸F, 449*
¹⁸F, "Ca, ⁶⁷Sr, ⁹⁹mSr and ⁶⁷Ga kinetics, 8
⁶⁷Ga citrate, 332*
interference by oral barium, 145, 146
¹³¹I, ⁶⁷Er, ⁶⁷Sm, 363*
⁶⁷Sr in metastatic carcinoma, 429*
⁶⁷Sr in osteoarthrosis, 109

**Book Review**
Radioaktive Isotope in Klinik und Forschung, 609
Thermoluminescent Dosimetry, 609

**Boron-10**
RBE in neutron capture therapy, 329*

**Brain**
angiography in CVA with ⁹⁹mTcO₄⁻, 401*
arteriography, ⁹⁹mTc, 358*
arteriovenous malformations, ⁹⁹mTcO₄⁻ and ¹⁹⁷Hg-chlormerodrin, 413*
cerebral lesions due to x-radiation, mouse fetus, 68
circulatory dynamics in cerebral vascular disease, 438*
comparison angiography, scanner and scintillation camera, for tumor, 349*
¹⁹⁷Hg and ⁹⁹mHg chelates, distribution, 446*
¹³¹In in EDTA and -DTPA compared with ⁹⁹mTcO₄⁻, localization, in hamsters, 290
K "MnO₄⁻ distribution, in rabbits, 205
preparation of ¹³¹In chelate in closed system, 318*, 452*
sцинтография, ⁹⁹mTcO₄⁻, 354*
sцинтография, 326*
⁹⁹mTc localization in tumor cell cultures, 349*
tissue vascularity in ⁹⁹mTcO₄⁻ and ¹⁹⁷Hg-chlormerodrin scans, 553
tumor, concentration ⁹⁹mTcO₄⁻ affected by perchlorate, in mice, 350*

**Brain, blood flow**
adjuvant with infrared thermography, 430*
computer analysis, 410*
fluorescence detection, 651
¹³¹In-in-EDTA, ⁹⁹mTcO₄⁻, scanning camera, 324*
⁹⁹mTcO₄⁻, 443*
⁹⁹mTcO₄⁻, autofluoroscope, 438*, 501
¹³³Xe, eight and sixteen detector scanners, 164

**Brain imaging**
adjuvant with echoencephalography, 430*
analysis of imaging techniques with digital simulation, 389*
comparison of scanner and scintillation camera, 359*
delayed imaging with ¹⁹⁷Hg-chlormerodrin and ⁹⁹mTcO₄⁻, 423*
echoencephalography and ⁹⁹mTcO₄⁻, choroid plexus, 403*
identification of gamma rays originating external to skull, 740
¹³¹In-DTPA and ⁹⁹mTcO₄⁻, comparison, 18
Cholesterol
1C-labeled, uptake in adrenal cortex, in dogs, 387*
Choline
intake, effect on 35Mn retention, 388*
Chromatography
separation of iodo compounds, 722
Chromium-48 cyclotron production, 376*
Chromium-51 absorption in elderly and diabetic subjects, 393*
cisternography, in monkeys, 321*
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet 4
%glycerophosphate for tumor localization, in rats, 318*
heat-denatured red cells for spleen scanning, 480
intestinal absorption, 331*
lymphocytes, kinetics in chronic lymphocytic leukemia, 404*
platelet life span and production, 395*, 426*
Chromium-51, red blood cells
blood volume, double tag, 31H-albumin, 400*
lung scanning in idiopathic pulmonary hemosiderosis, 106, 433*
measurement of blood exchange, 408*
spleen scanning, ACD damaged, 357*
spleen scanning and clearance, 410*
Cisternography
evaluation of short-lived radioactive agents, in monkeys, 321*
35I-HSA, spinal cord dosimetry, 340*
35mIn colloid, 376*
simultaneous brain scan, 348*
Cobalt-57
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
Schilling test and plasma level of vitamin B 12, 457*
Cobalt-58
hematoporphyrin complex, lymph node localization, in dogs, 381
Cobalt-60
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
vitamin B 12 uptake with whole-body counter, 431*
Collimator
diverging, resolution by MTF, 337*
diverging, scintillation camera, 197, 425*
line source response, MTF, 394*
nonfocused, 3D scanning, 391*
5-in. focus, lateral view thyroid and kidneys, 459*
Colloids
albumin microspheres, 35Tc, transpulmonary shunting, 344*
distribution, effect of electrophoretic mobility, 387*
human serum albumin as stabilizer for 35S colloids, 294
53mIn-Fe, preparation, liver and spleen imaging, 597
particle sizing, 387*
stabilization by polyhydric alcohols, 607
35mTc, 51Er for cisternography in monkeys, 321*
35mTc(Fe(OH)) 3 , preparation and lung scanning, 737
35mTc-S, stabilized with HSA, 461*

Computer
aid to depth discrimination, dual isotope technique, 188
calculation of well scintillator efficiency, 371*
desk-top digital, 327*
digital analysis and display of scans, 389*
digital, differential-operator focusing, scanner, 209
digital, estimation of 35I thyroid uptake from scintiscan matrices, 258
functional image from dynamic measurements, 347*
gamma spectrum analysis, 417*
instruction in nuclear medicine, 339*
interpretation of distribution patterns, thyroid, 618
interpretation of scans, 404*
35I-rose bengal kinetics, 450*
kidney function, 418*
kidney perfusion and function, scintillation camera, 435*
microfilming system, 562
on-site analysis of scintillation camera data, 325*
platelet life span and production, 426*
presentation of data for chromatographic separation of
131I compounds, 722
processing images, 150
pulmonary-function studies, 353*
quantitative studies, scintillation camera, 419*
radiopharmaceutical inventory, 405*
regional pulmonary dynamics, 438*
scanning process simulation, 416*
simulated brain images, analysis of techniques, 389*
simulated kidney scans, performance of observers, 369*, 415*
thyroid scanning, data averaging and analysis, 393*
tomography with a scintillation camera, theoretical considerations, 654
training aid in nuclear medicine, 660
visualization and enhancement of gamma camera output, 444*

Contrast efficiency function
spatial resolution characteristics of scanners, 433*

Copper-64 gastrointestinal absorption, 591
Copper-67 absorption and retention in hemochromatosis, 402*
detection of the heterozygote of Wilson's disease, 143
metabolism in Wilson's disease, 320*
total-body turnover, Wilson's disease, 451*

Coronary blood flow
semiconductor detector, 345*

Coumarin
effect on thyroid hormone binding in serum, 511

Counting
35I and 35Se in the same sample, 46

Cows
see Generators

Cyclotron
*Ga production, 343*
131I production, 371*
isotope production, 376*

Cytoamine
radiation-protection of leukocytes, 495

Cystic Fibrosis
determination by trace elements, 730

Data blending
magnifying glass, 417*

SUBJECT INDEX
Data processing with camera, 369°

Detector
absolute detection efficiency of NaI(Tl) well crystal, 428*
Ge(Li), 131I thyroid, 136
high-resolution gamma-ray spectrometry, fingerprints, 730
semiconductor, catheter technique for cardiac output, 713
semiconductor, for heart, 345*
Si(Li), fluorescence detection, cerebral blood flow, 651

Diabetes
pancreas scanning, 453*

Diamond dust
14N labeled, effect of particle size on organ distribution, 442*

Diiodotyrosine
chromatographic separation, 722

Digital computer
see Computer

Display system
analog-digital, 382*
serial lung scans, pulmonary embolism, 373*
three-dimensional, camera, 326*
three-dimensional, eight detector, 363*

Diuresis
hyperbaric effects, 360*

Diuretics
augmentation of 131I uptake in thyroid cancer, 340*

DNA
effect of radiation on synthesis and thymidine incorporation, 624

Dolphins
water intake, 375*

Dopamine
14C- in adrenal medulla and neuroblastoma, 93

Dosimetry
absorbed dose estimation, mathematical phantom, MIRD pamphlet #5
book review,
Thermoluminescent Dosimetry, 609
decay schemes and nuclear parameters, MIRD pamphlet 4
dose rate in radiological and nuclear medicine procedures, 295
131I-hippuran, renograms in pediatrics, 423*
131I, for thyroid, 752
permissible levels for bone seekers, 406*
spinal cord, 141HSA cisternography, 340*
**Tc-albumin, in pregnancy, 224

Echoencephalography
use with **TcO4- brain imaging, 403*, 430*

Education
computer, a training aid in nuclear medicine, 660
explanation of procedures to patients, 462*
master's program in radiopharmacy, 383*
Society of Nuclear Medicine Education and Research Foundation, 257

Electrophoretic mobility
spleen trapping of altered RBC's, 391*
tissue distribution of metabolizable colloids, 387*

Erbium-171
bone imaging, 363*
cisternography in monkeys, 321*
HEDTA complex for bone imaging, in rabbits, 49

Erythrocyte
see Red blood cell

Eye
blood flow measured with 133Xe, 333*

Fat malabsorption
14C-fatty acids, specific activity of expired 14CO2, 385*

Fetus
**Tc-albumin, distribution and dosimetry, 224

x-radiation effects, in mice. 68

Fibrinogen
131I labeled, survival study, 322*
131I labeling, 410*

Flow rates
measurement, branched system phantom, 525

Fluorescence
cerebral blood flow, 651

Fluorine-18
autoradiography, rabbit kidney, 362*
bone imaging for radiation damage, 320*
bone scanning, 449*
bone scanning, comparison with "Ca, 85Sr, 88Sr and 86Ga, 8
cyclotron production, 376*
decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4

Folate
human deficiency, oxidation of beta carbon of serine, 329*

Function
computer images, dynamic, 347*

Gallbladder
111m-rose bengal, function with camera, 445*
K "MnO4-, distribution, in rabbits, 205
radioimmunoassay of cholecystokinin using 131I, 743

Gallium-67
citrate, soft tissue tumor and bone scanning, 103, 332*
citrate, for tumor scanning, 103
cyclotron production, 343*
uptake in soft tissue tumors, 406*

Gallium-68
chemistry of EDTA complex, 396*
citrate for bone scanning, comparison with 18F, 44Ca, 85Sr and 88Sr, 8
Fe(OH)3 macroaggregates for lung with positron camera, in animals, 328*

Gastric secretion
**TcO4-, 367*

Gastrin
radioimmunoassay in human serum using antiserum, 746

Gastrointestinal tract
absorption, 198Au marker, 331*
absorption of copper, 591
absorption of **Fe, in dogs, 392*

Gelatin
NaBH4 method of labeling with **Tc, 443*

Generator
143In chemistry, 452*, 646
133Xe, pulmonary dynamics, 384*
**Mo-**Tc, elution, 461*
yields of **TcO4-, 456*

Glomerular filtration rate
**Co-vitamin B12, schistosomiasis, 398*
**H-mannitol, 411*
131I-Na-ithalamate, 297, 298
111In-DTPA, 422*
111In-EDTA, 400*

Glucose
turnover, in dogs, using 14C, 98

Glycerocephosphate
**Cr labeled for tumor localization, in rats, 318*

Gold-198
cisternography, simultaneous brain scan, 348*
decay scheme, nuclear parameters, radiation dose, MIRD pamphlet #4
determination in fingernails, 730
dual-channel pancreas scanning, with 75Se-selenomethionine, 78, 153
dual-channel scanning, focal lesion of liver, 348*
false-positives in liver imaging, 334*
labeled iron oxide particle aerosol, in airway obstruction, 460*

Volume 10, Number 12

SUBJECT INDEX
liver imaging with autofluoroscope and scanner, 441*
liver metastasis, scanning, 434*
liver scanning, 628
liver scanning, comparison with $^{99m}$Tc-S colloid, 391*
marker for intestinal absorption, 331*
mediastinal lymph node, scanning, 749
sub-phenolic absorbes, 448*
Graft-versus-host reactions
study using radioisotope techniques, 396*
Grignard
preparation $^{14}$C-carboxylic acids, 382*
Heart
angiography, ventricular and aortic disease, 351*
cardiac blood-flow, 270
cardiac output with $^{131}$I-HSA, 458*
cardiac output using semiconductor detector, 713
cardiac stroke volume, camera, 369*
coronary blood flow and cardiac output, 417*
coronary blood flow, coincidence counting of $^{85}$Rb, 336*
coronary blood flow, in dogs, 323*
evaluation of compressive heart disorders with $^{99m}$Tc and $^{111}$In-HSA, 373*
imaging, cardiac shunts, 344*
mitral valve disease, $^{99m}$TcO$_4^-$ angiography, 357*
myocardial blood flow using $^{82}$K, 437*
myocardial blood flow with $^{133}$Xe, 412*
myocardial clearance of $^{85}$K and $^{85}$Rb, 702
myocardial infarcts, potential of toulidine blue, 413*
myocardium visualization with $^{75}$Se-selenomethionine, 155
pericardial effusion, combined heart-lung scan, 390*
pericardial effusion, $^{99m}$TcO$_4^-$ angiography, 233, 430*
pericardial effusion, ultrasound and radionuclide imaging, 429*
sodium and water space studies, 407*
transmission imaging, $^{99m}$Tc, 381*
transmission imaging, $^{99m}$Tc point source, 439*
transpulmonary shunting, quantification, 344*
Hemochromatosis
$^{55}$Mn and $^{65}$Cu absorption and retention, 402*
Hemoglobin
$^{14}$C-labeled, radioassay, 261
Hippuran
see iodine-131, hippuran; Kidney renography
Hodgkin's disease
liver-spleen imaging with $^{99m}$Tc-S colloid, 450*
Hormones
radioimmunoassay of pancreatic yin cholecystokin in human serum, 743
Hydrocephalus
$^{99m}$TcO$_4^-$ for treatment, 322*
Hydrogen-3
see Tritium
Hypertension
evaluation of $^{199}$Hg-chlormerodrin kidney scan, 399*
total-body potassium, 427*
Hypothyroidism
propanolol and $^{131}$I treatment, 403*
Hypoplastic anemia
radioisotope studies, 410*
Hypothalamus
$^{75}$Se-selenocystine localization, in dogs, 321*
Idiopathic pulmonary hemosiderosis
$^{99m}$Tc-RBC lung scanning, 433*
Indicator
thymol blue for $^{131}$In-Fe(OH)$_3$ preparation, 633
Indium
long term effects of in administration, 447*
Indium-111
lymphatic scintiphotography with colloid, 337*
tumor localization, in rats, 343*
Indium-113m
agents for cisternography in monkeys, 321*
albumin aerosol for inhalation scanning, 428*
albumin aerosol for inhalation scanning, 428*
alanine hydroxide preparation for lung, animal studies, 377*
blood plasma volume measured by $^{111}$In-transferrin space, 383*
blood volume, comparison with $^{131}$I-albumin, 402*
blood volume determination, 397*
collod preparation, liver and spleen imaging, 597
decay scheme, nuclear parameters, radiation dose, MIRD
packlet 4
gelatin complex, placent imaging, 324*
iron hydroxide for dynamic lung studies, 324*
iron hydroxide in pulmonary embolism, 331*
kinecs of labeled transferrin in pregnant rats, 338*
labeling of albumin microspheres, 487
macroaggregates, lung scintiphotographs and quantitative analysis, 409*
preparation of albumin aggregates, 368*
preparation of organ specific compounds in closed system, 318*
transferrin, plasma volume, 442*
Indium-113m, chelates
DTPA, brain blood flow, 324*
DTPA, brain imaging, compared with $^{99m}$TcO$_4^-$, 18
DTPA complex for GFR, 422*
-EDTA and -DTPA, brain, compared with $^{99m}$TcO$_4^-$, in hamsters, 290
EDTA, GFR, 400*
preparation of brain and kidney agents, 452*
Indium-113m, iron hydroxide
preparation using indicators, 633
Indium-114
DTPA complex, metabolism, 409*
Infrared thermography
carotid occlusive disease, cerebral blood flow, 430*
Insulin
$^{125}$I-labeled, cisternography, in monkeys, 321*
Iodine-121
cyclotron production, 376*
Iodine-123
compared to $^{131}$I for thyroid studies, 381*
cyclotron production, 371*, 376*
decay scheme, nuclear parameters, radiation dose, MIRD
packlet 4
diagnostic application, 444*
effect of $^{131}$I on thyroid scanning, 457*
thyroid studies with Ge(Li) detector, 136
Iodine-124
contamination in $^{131}$I, effect on thyroid scanning, 381*, 457*
Iodine-125
albumin, blood volume, double tag, $^{99m}$Cr-RBC, 400*
albumin, kidney blood flow with camera, 411*
and $^{131}$I-hippuran, double isotope renography, 375*
angiotensin II, assay of renin, 347*
autoradiography, "hot" thyroid nodule, 691
chloroquine analogs, concentration in malignant melanomas, 323*, 448*
counting with $^{75}$Se in the same sample, 46
decay scheme, nuclear parameters, radiation dose, MIRD
packlet 4
double isotope method of depth discrimination, with $^{131}$I, 188
gamma radiation absorption by skull in brain scanning, 184
lymphocytes, metabolic fate, in rats, 327*
phenylalanine analogs, uptake in parathyroid and pancreas, in dogs, 398*
phenylalanine, distribution in mice, 219
rectilinear transmission scanning for bone mineral content, 379*
scattered radiation, 417*
thyroxine, serum T, determination, 374*
toluidine blue, distribution in rat, 386*
tryptophane, distribution, 342*

**Iodine-131**
agents for cisternography, in monkeys, 321*
anti-fibrin antibody, in rheumatoid arthritis, 371*
autoradiography, "hot" thyroid nodule, 691
chloroquine, in malignant melanoma, 323*
chloroquine therapy, malignant melanoma, in dogs, 354*
chromatographic separation of iodo compounds, 722
comparison with 131I for thyroid studies, 381*
decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4
diuretic augmentation of uptake in thyroid cancer, 340*
double isotope method of depth discrimination, with 131I, 188
fibrinogen labeling, 410*
fibrinogen, survival study, 322*
gamma radiation absorption by skull in brain imaging, 184
iothalamate and 115mIn-EDTA for GFR, 400*
large initial therapy dose, 341*
lymphocytes, metabolic fate, in rats, 327*
lysozyme, autoradiography, rabbit kidney, 362*
method for determining serum thyroxine, 428*
minimum activity required for thyroid studies, 475
Na-iothalamate, GFR, 297, 298
polyvinylpyrrolidone (PVP), retention and storage sites, 295, 296
radioimmunoadsorption of pancreatezym in cholecystokinin in
human serum, 743
rose bengal hepatogram, 435*
rose bengal kinetics, computer analysis, 450*
rose bengal, liver and gallbladder function, 445*
rose bengal liver scanning, 628
tetracycline, distribution, in cats, 697
therapy of progressive malignant exophthalmos, 390*
therapy in children, followup, 586
therapy in thyroid carcinoma, survival, 378*
thyroid function, compared with 189Re, in rats, 359*
thyroid hormones and iodide, chest scanning in pneumonia, 424*
thyroid imaging, 451*
thyroid trapping function, 421*
thyrotocicosin, propanolol, 403*
thyroxin, serum T4 assay, 565
triolein, purification, 353*
uptake, effect of thyrotropin in Graves' disease, 246
whole-body retention, measurement of thyroid function, 459*

**Iodine-131, albumin**
blood volume, comparison with gelatin stabilized 115mIn, 402*
cardiac blood pool and lung imaging, 429*
cardiac output, 417*, 458*
evaluation of compressive heart disorders, 373*
lung distribution and clearance of aerosol, 361*
measurement of blood exchange, 408*
macroaggregated RES function and scanning, 453*
macroaggregated, structure, 414*
microsphere labeling, 373*
pericardial effusion via combined heart-lung scan, 390*
scapul and skull content, 177
scanning agent in rheumatoid arthritis, 371*
transcapillary protein transport, 442*

**Iodine-131, hippuran**
autoradiography, rabbit kidney, 362*
double isotope renography with 131I hippuran, 375*
kidney blood flow with camera, 411*
kidney function using a camera and computer, 418*
kidney imaging, 545
kidney visualization in renal insufficiency, 333*
radiation dosimetry, renograms, 423*
renal excretion models, 664
renal plasma flow, 735
renal tubular passage times, physiological determinants, 641
renography, comparison with urography, arteriography and
function studies, 603
renography, effects of hydration and blood flow, 67
schistosomiasis, renal function, 398*

**Iodine-131, macroaggregated albumin**
blood flow in atelectatic lung, in dogs, 365*
complete pulmonary artery occlusion, 440*
disappearance rate from lung, 560
intra-arterial injection, for liver, 514
lung, autofluorescence imaging, 341*
lung perfusion in embolism, 571
lung perfusion, quantitative, 409*
oblique lung imaging, 420*
pericardial effusion via combined heart-lung scan, 390*
pulmonary embolism, 331*
radiation-induced pulmonary ischemia, in mice, 347*
radioactive pulmonary emboli, 415*
regional pulmonary defects, 427*
renal blood flow by autoradiography, in rabbits, 362*
sub-phrenic abscess, 448*
ventilation-perfusion studies, 420*

**Iodine-133**
dosimetry, 752
tyroid uptake, 286

**Iothalamate**
131I labeled, GFR, 297, 298

**Iron-59**
cyclotron production, 376*

**Iron-59**
bone marrow cells, post-irradiation, in rabbits, 361*
decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4
distribution and kinetics, 378*
DTPA complex, metabolism, 409*
dual labeling of erythrocytes, with 75Se, in rats, 122
ferrokinetics in hypoplastic anemia, 410*
gastrointestinal absorption, in dogs, 392*
kinetcs of labeled transferrin in pregnant rats, 338*
whole body scanning, 469

**Isoprotenerol**
effect on myocardial blood flow, in dogs, 83
effect on pulmonary blood volume, 427*

**Kidney**
detectability of lesions, count density, 369*, 415*
excretion model 131I hippuran, 664
function using 153Hg Cls, 367*
functional image from regional rate constants, by computer, 347*
197Hg-chlomerodrin, hypertension by scanning, 399*
153Hg and 197Hg chelates, distribution, 446*
197Hg-chlomerodrin excretion, in baboon, 540
131I-hippuran scanning in renal insufficiency, 333*
imaging with 131I-hippuran, 545
115mIn-chelates, preparation, 452*
K 153MoO4, distribution, in rabbits, 205
lateral scanning view, 5-inch focus collimator, 459*
penicillin, effect on retention of 197Hg-chlomerodrin, 413*
preparation of 115mIn-chelate in closed system, 318*
radiouclide distribution by autoradiography, in rabbits, 362*
sceintiphrography and ultrasonography for mass differen-
tiation, 367*

**Kidney, glomerular filtration rate**
see Glomerular filtration rate

**SUBJECT INDEX**
Kidney, renography
blood flow with 131I-hippurate and 125I-albumin, 411*
compared with IVP, in pediatrics, 370*
compared with urography, arteriography and function
studies, 603*
double isotope, 375*
evaluation methods, 40
effects of hydration and blood flow, 672
131I-hippuran, computer and scintillation camera, 418*
perfusion and function, scintillation camera and com-
puter program, 435*
plasma flow with 131I-hippuran, 735
schistosomiasis, 125I-hippuran, 398*
transplants, 133
tubular passage times, physiological determinants, 401*, 641
125I-Yb-DTPA complex for function studies, 385*
Kit
sterile 111In in organ specific compounds, 318*
 sterile 99mTc-HSA, 328*
 99mTc-albumin microspheres, 368*
 99mTc-macro- and microaggregated albumin, 342*
Knee
3-D representation of isotope deposition, 388*
Krypton-81m
 generator, pulmonary dynamics, 384*
Krypton-85
 coronary blood flow, semiconductor detector, 345*
Leukocytes
 99mTc-DFP labeled, kinetics in chronic granulocytic leu-
kenia, 449*
radiation-protection by cysteamine, 495
Lipid
proteine ratios, in vitro tissue, 366*
Liquid scintillation
 counting 99mTc-hemoglobin, 261
counting 99mTcSO4 in plasma and urine, 284
stable liquifluor solution for 99mTc in protein-free plasma,
263
whole-body potassium counting, 426*, 427*
Liver
 activation analysis, bromine and iodine, 447*
blood exchange measured with 125I-RBC and 131I-HSA,
408*
blood flow with 133Xe, in dogs, 330*
choline intake and 51Mn retention, 388*
 51Cu metabolism in cirrhosis, 320*
 64Cu metabolism in Wilson’s disease, 320*
effect of particle size on organ distribution, 442*
 99mTc deposition, whole-body scanning, 469
 function studies with 125I-rose bengal, 435*
 99mTc labeled compounds, studies in animals, 396*
 Hodgkin’s disease, 99mTc-S colloid imaging, 450*
intra-arterial 99mTc-macroaggregated albumin, 514
123I-polynvinlypyrolidone (PVP) concentration, 295, 296
125I-rose bengal, computer analysis of kinetics, 450*
125I-rose bengal, function with camera, 445*
 99mTc microaggregated albumin, function and imag-
ing, 453*
 111In-Fe colloid, preparation and imaging, 597
K *MnO4, distribution, in rabbits, 205
K *MnO4, distribution, in rabbits, 205
 *Mn and 64Cu absorption and retention in hemochroma-
tosis, 402*
 normal growth rate, 372*
 pliability using *99mTc-S colloid, 416*
 protein synthesis, post-irradiation, in rats, 351*
 quantitative function with *111In colloid, 409*
 sub-phrenic abscess, imaging, 448*
Liver imaging
 adjunction to celiac angiography, 628
 111In-Au, with Autofluoroscope and scanner, 339*, 441*
 Autofluoroscope, sequential count subtraction, 439*
 false-positives, extrinsic disease, 334*
preparation of 111In colloid in closed system, 318*
*99mTc-dioxide, preparation and localization, 346*
*99mTc-S colloid, 420*, 421*
*99mTc-S colloid, cyst-tumor differentiation, 319*
Liver scanning
 breathing artifacts, Dynapix and *99mTc compounds, 435*
comparison between *111In colloid and 99mTc-S colloid,
391*
dual channel scanning for focal lesions, 348*
111In-albumin aggregate, in animals, 368*
metastasis with *99mTc, 434*
preoperative evaluation of patients with cancer, 365*
*99mTc-S colloid, children, 433*
*99mTc-S colloid, report of 1,000 cases, 327*
variable appearance in hepatoma, 449*
Lung
 blood flow in atelectasis, in dogs, 365*
chronic obstructive pulmonary disease, residual Na, 444*
comparison of scintigraphy and angiography, 380*
comparison of scintigraphy, angiopneumography and bronchospirometry, 174
complete pulmonary artery occlusion, 440*
disappearance rate of 111I-MAA, 560
 dynamics using *99mTcKr, 384*
effects of isoproterenol on pulmonary blood volume, 427*
effect of particle size on organ distribution, 442*
fatal pulmonary embolism, 29
 functional image from regional rate constants, by com-
puter, 347*
I-HSA aerosol, distribution and clearance, 361*
inhalation-perfusion studies in pulmonary embolism,
427*
inhalation scanning with *123Xe in chronic obstructive air-
ways disease, 345*
K *MnO4 distribution, in rabbits, 205
microcirculation defect in chronic obstructive pulmonary
disease, 366*
 perfusion in embolism, 571
radiation induced ischemia, in mice, 347*
radioactive pulmonary emboli, 415*
regional pulmonary dynamics, with computer, 353*, 438*
 regional and quantitative perfusion, 409*
 regional ventilation perfusion ratios with *123Xe and
 *111In-Fe(OH)3, 324*
*99mTc Fe(OH)3, preparation and scintigraphy, 683
ventilation-perfusion studies with *123Xe, 331*, 355*, 374*,
412*, 418*, 420*
Lung imaging
 Autofluoroscope, 341*
diverging collimator for scintigraphy, 425*
oblique with *111In-MAA, 420*
radiation, 430*
 sub-phrenic abscess, 448*
 transmission, *99mTc point source, 439*
Lung imaging agents
*99mTc-iron oxide aerosol, in airway obstruction, 460*
111In-Au(OH)3, 377*
111In-Au(OH)3, in closed system, 318*
111In-Au(OH)3, using indicators, 633
111In-MAA, 368*
 *Ga-Fe(OH)3, macroaggregates, 328*
 *Ga labeled compounds, studies in animals, 396*
 99mTc-albumin microspheres, 368*, 432*
*99mTc-macroaggregated thionin, 117, 454*
*99mTc-MAA, 394*
*99mTc-S colloid plus HSA, 621
*99mTc-S; macroaggregates, 402*
Lung scanning
*99mTc-RBC, idiopathic pulmonary hemosiderosis, 106, 433*
 emphysema, a-1-antitrypsin deficieny, 687
 new display system for serial scans, pulmonary embo-
 lism, 373*
 patient position for AP view, 400*
pericardial effusion via combined heart-lung scan, 390*

""""Tc-Fe(OH)₃, 737

transmission, """"Tc tank source, 381*

Lutetium-177

bone imaging, 363*

HEDTA complex, bone imaging, in rabbits, 49, 320*

Lymph node

irradiation with labeled metallohematoporphyrins, 333*, 581

scanning mediastinal, 749

Lymph node system

""""Tc-sulfur colloid, visualization in rabbits, 390*

scintigraphy with ¹¹¹In colloid, 337*

Lymphocytes

¹⁸⁶Cr chromate labeled, kinetics, 404*

metabolic fate, ¹³¹I- and ¹³¹I-labeled, in rats, 327*

²⁵⁷Se-selenomethionine test for globulin synthesizing capacity, in vitro, 63

Macroaggregated albumin

see Iodine-131, macroaggregated albumin; Technetium-99m

Manganese-54

absorption and retention in hemochromatosis, 402*

retention, relationship to choline intake in rats, 388*

Manganese-56

K⁺MnO₄, distribution, in rabbits, 205

Mannitol

¹⁴H labeled for GFR, 411*

stabilization of """"Tc-S colloid, 607

Mathematical model

quantification of physiological systems, 405*

Medical imaging department

radiography, radioisotope and ultrasound scans, tomography, 426*

Medical Internal Radiation Dose Committee

absorbed fraction, MIRD Pamphlet # 5
decay schemes and nuclear parameters, MIRD Pamphlet # 4

Melanoma

concentration of ¹³¹I analogs, 448*

¹³¹I- and ¹³¹I-chloroquine, distribution, 323*

¹¹¹I-chloroquine, therapy, in dogs, 354*

Mercury-197

celates, distribution and kidney function, 446*

chloride, kidney, 367*

decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4

MHP damaged RBC's for splenic function, 615

Mercury-197, chlormerodrin

brain lesions, tissue vascularity, 553*

brain scanning arteriovenous malformations, 413*
evaluation, renovascular hypertension, 399*

kidney visualization in renal insufficiency, 333*

Mercury-203

BMHP for splenic function, 410*

celates, distribution and kidney function, 446*

decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4

Mercury-203, chlormerodrin

autoradiography, rabbit kidney, 362*

delayed brain imaging, 423*

D-Penicillamine treatment, effect on kidney retention, 413*

kidney excretion, in baboon, 540

Metastatic prostatic cancer

³¹P treatment, a new method, 430*

Methacholine

effect on pulmonary blood volume, 427*

Microfilm

computer compatible records system, 562

Microspheres

amylose, preparation and """"Tc labeling, 373*
gelatin, preparation and """"Tc labeling, 373*

Microspheres, albumin

¹¹¹In labeling, 487

preparation, """"I and """"Tc labeling, 373*

""""Tc-labeled, lung imaging, 432*

""""Tc labeled, pulmonary shunting, 344*

""""Tc labeling, 368*

Millipore filtration

quality control of """"Tc-sulfur colloid, 399*

Modulation transfer function

comparison of scanner and scintillation camera, 359*

figure of merit for imaging systems, 431*

response of collimators to a line source, 394*

scattered radiation from """"I, 417*

scintillation camera with diverging collimator, 337*

Molybdenum-99

detection in separated """"Tc, 517

eclusion of """"Mo-⁹⁹Tc generator, 461*, 550

Monoiodotyrosine

chromatographic separation, 722

Muscle

blood flow, functional image, 347*

Neohydrin

see Mercury-197, chlormerodrin; Mercury-203, chlormerodrin

Neutron activation analysis

liver, bromine and iodine, 447*

nitrogen and proteins, in mice, 192

trace elements in fingernails, 730

whole-body calcium, 360*

Neutron-capture therapy

RBE of heavy ionizing particles, 329*

Nitrogen

total-body content by neutron activation analysis, in mice, 192

Nitrogen-13

cycloprod production, 376*

diamond dust, effect of particle size on organ distribution, 442*

Norepinephrine

effect on myocardial blood flow in dogs, 83

Nuclear medicine

computer assisted instruction, 339*

Oxygen-15

cycloprod production, 376*

Palladium-103

decay scheme, nuclear parameters, radiation dose, MIRD pamphlet 4

Palladium-109

hematoporphyrin for lymphatic irradiation, 333*

Pancreas

angiography with """"⁹⁹TcO₄⁻, in dog, 389*

dual-channel scanning, """"Au and """"Se-selenomethionine, 78, 155

¹³¹I labeled phenylalanine analogs, uptake, in dogs, 398*

¹³¹I-phenylalanine, in mice, 219

liver subtraction, 459*

radioimmunoassay of pancreozymin using """"I, 743

""""Se-L-selenocystine and """"Se-DL-meso-selenocystine metabolism, 575

""""Se-selenomethionine imaging, 430*

""""Se-selenomethionine scanning in diabetic patients, 453*

Parathyroid

¹³¹I-phenylalanine analogs, uptake, in dogs, 398*

""""Se-selenomethionine distribution in hyperparathyroidism, in dogs, 363*

Pediatrics

bone marrow imaging, """"⁹⁹Tc-S colloid, in thalassemia, 351*

""""I-therapy for hyperthyroidism, followup, 586

liver scanning with """"⁹⁹Tc-S colloid, 433*

premedication for """"⁹⁹TcO₄⁻ brain scanning, 254

renogram compared with IVP, 370*

scintigraphy of central circulation dynamics, 338*
Penicillamine
effect on kidney retention of $^{203}$Hg-chlormerodrin, 413*
Perchlorate
effect on compartmental distribution of $^{99m}$TcO$_4^-$, 424*
effect on $^{99m}$TcO$_4^-$ clearance from thyroid, 637
Phantom
branched system, for flow rates, 525
depth discrimination, double isotope technique, 188
design for dynamic function, 416*
mathematical, estimation absorbed dose, MIRD Pamphlet #5
Phenyllalanine
$^{13}$I, distribution, in mice, 219
$^{18}$I-labeled analogs, uptake in parathyroid and pancreas, in dogs, 398*
Phosphorus-32
cancer detection, semiconductor detector, 345
cardiac output using semiconductor catheter detector, 713
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
dFP leukokinetics in chronic granulocytic leukemia, 449*
therapy, bone metastases, 376*
therapy, metastatic prostatic cancer, 430*
therapy, polycythemia vera, 392*
Photography
record-keeping system for scintillation camera images, 460*
selection of polaroid film for scintophotography, 127
Placenta
imaging with $^{131}$In gelatin complex, 324*
$^{99m}$TcO$_4^-$ scanning with 10-cryystal detector, 449*
Plasma
see Blood plasma
Plasmapheresis
treatment of thyrotoxic crisis, 319*
Platelet
aggregation in polycythemia vera, determining therapy, 392*
$^{51}$Cr-labeled, life span and production, 395*, 426*
Pneumonia
chest scanning with $^{18}$I-thyroid hormones, $^{18}$I, $^{99m}$TcO$_4^-$, 424*
Polyvinylpyrrolidone (PVP)
$^{131}$I labeled, retention and storage sites, 295, 296
Potassium-40
whole-body concentration in Duchenne muscular dystrophy, 1
whole-body counting, liquid-scintillation, 426*, 427*
Potassium-42
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet 4
myocardial blood flow, 437*
residual Na in chronic obstructive pulmonary disease, 444*
President's letter
annual meeting, 149, 663
Board of Nuclear Medicine, 55, 257, 663
bylaws, 257
Society of Nuclear Medicine Education and Research Foundation, 257
technology training program, 149, 663
Propanolol
thyrotoxicosis, $^{131}$I treatment, 403*
Prostate gland
$^{63}$Zn dosimetry for scanning, 336*
Protein
-lipid ratios, in vitro tissue, 366*
synthesis in irradiated liver, in rats, 351*
total-body content by neutron activation analysis, in mice, 192
Protein-bound iodine (PBI)
compared with serum thyroxine assay, 160
Pulmonary function
see Lungs
Quality control
$^{99m}$Tc-sulfur colloid, Millipore filtration, 399*
Radiation
effects of supraventricular irradiation through parabiosis, 328*
effect on DNA synthesis, 624
effect on monocarbon fragment transport, 424*
Radiation arthritis
tolerance of articular cartilage, 433*
Radiation damage
bone and bone marrow, therapy, 320*
marrow RE cell and erythron, in rabbits, 361*
protein synthesis in liver, in rats, 351*
pulmonary ischemia, in mice, 347*
irradiation-protection of leukocytes by cysteamine, 495
x-radiation effects on mouse fetus, 68
Radiation dose
hand, from $^{99m}$Tc, 423*, 732
Radiation therapy
$^{43}$Ca kinetics in bone metastases, 338*
Radiography
see Autoradiography
Radiochemicals
see Heart
Radiotherapy
correlation with brain scintiphotography, 419*
Radioimmunoadsorbent
gastrin in human serum using antiserum, 746
$^{125}$I, pancreozymin and cholecystokinin in human serum, 743
Radiopharmaceuticals
assay, 147
$^{18}$I capsule count variation, effect on thyroid uptake, 461*
inventory by computer, 405*
NIH Radiopharmaceutical Service, 612
quality-control system, 558
M.S. program at Univ. S. Calif., 383*
Red blood cells
$^{51}$Cr-labeled, double tag blood volume, $^{60}$I-albumin, 400*
$^{51}$Cr labeled, heat-denatured, for spleen scanning, 480
dual-labeling with $^{131}$I and $^{59}$Fe, in rats, 122
$^{197}$Hg-MHP damaged, splenic function, 615
spleen trapping, 391*
Red-cell mass
use of total body hematocrit, 350*
Red-cell survival
change in spaceflight, 346*
Relative biological effect
$^b$-neutron capture therapy, 329*
Renal, renography
see Kidney, renography
Renin
radioimmunoassay of angiotensin II, 347*
Resolution
contrast efficiency function of scanners, 433*
Reticuloendothelial system
distribution of colloids, electrophoretic mobility, 387*
effect of particle size on organ distribution, 442*
$^{99m}$Tc-sulfur colloid, H$_2$S preparation, 386*
Rhenium-188
thyroid function, in rats, 359*
Rheumatoid arthritis
radiogold installation, 433*
Rose Bengal, $^{18}$I-labeled
computer analysis of kinetics, 450*
hepatogram, 435*
leber and gallbladder function, 445*
leber scanning, 628
Rose Bengal retention test
comparison with BSP test, 416*
Rubidium-81
generator for $^{85}$Kr, 384*
Rubidium-84
  coronary blood flow, 336*, 417*
  myocardial blood flow, in dogs, 83
Rubidium-86
  clearance by myocardium, 702
tumor and organ growth, 440*
  whole-body metabolism in Duchenne muscular dystrophy, 1
Salivary glands
  75mTcO, for scanning, 334*
Samarium-153
  bone imaging, 363*
  HEDTA complex for bone imaging, in rabbits, 49
Scanner, dual channel
  brain, 155
  brain and cisternal system, 348*
  depth discrimination, 188
  focal lesions in liver, 348*
  pancreas, 78, 155
Scanning
  see also, Specific organs
  breathing artifacts in liver visualization, 435*
  center of activity with dual head, 404*
  computer simulation, 416*
  detectability of lesions, function of count density, 415*
  Dynapix, optimizing brain scans, 456*
  line spacing and time-constant selection, 414*
  liver imaging with 111Au, 441*
  thermal and radionuclide, 446*
  two dimensional image analysis, 340*
Schilling test
  plasma level of 7Co-vitamin B, 457*
Schistosomiasis
  131I-hippuran renal function; 7Co-vitamin B, GFR, 398*
Selenium
  metabolism during vitamin-E deficiency, 441*
Selenium-75
  counting with 75I in the same sample, 46
  decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet 4
  distribution of Se-carboxylic acids, 439*
  L-selenocystine and DL-meso-selenocystine metabolism, 575
  uptake of selenocystine in hypothalamus, in dogs, 321*
Selenium-75, selenomethionine
  distribution and concentration, in man, 709
distribution in hyperparathyroidism, in dogs, 363*
  dual-channel brain scanning with 75mTcO, 155
dual channel pancreas scanning, 78, 155
dual-labeling of RBC’s with 75Se, in rats, 122
  focal lesions of liver, dual-channel scanning, 348*
  globulin-synthesizing capacity of lymphocytes, in vitro, 63
  liver subtraction in pancreas scanning, 459*
  pancreas imaging, 430*
  pancreas scanning in diabetic patients, 453*
  protein synthesis in liver, post-irradiation, in rats, 351*
  tumor and organ growth, 440*
  uptake in cold thyroid nodules, 452*
  visualization of myocardium, 155
Selenocystine
  7Se labeled, uptake in hypothalamus, in dogs, 321*
Serine
  human folate and vitamin B, deficiency, 329*
Siamese twins
  isotope studies, 370*
Silver-111
  hematoporphyrin for lymphatic irradiation, 333*
Sodium-22
  residual Na in chronic obstructive pulmonary disease, 444*
  space studies following cardiac surgery, 407*
Sodium-24
  decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
  determination in fingernails, 730
  water intake, in dolphins, 375*
Sodium borohydride
  labeling with 77mTc, 443*
Soft tissue analogs
  physiochemical, time-dose effects in therapy, 398*
Soft tissue tumor
  99mGa uptake, 103, 332*, 406*
Spinal cord
  dosimetry, 121-I-HSA cisternography, 340*
Spleen
  7Cr labeled, ACD damaged RBC’s, 357*
  7Cr labeled, heat denatured RBC’s, 480
dual-labeled erythrocytes, in rats, 122
effect of particle size on organ distribution, 442*
function with 77mCr-RBC and 77mHg-BMHP, 410*
77mHg-HMP damaged RBC’s, functional capacity, 615
Hodgkin’s disease, 77mTc-S colloid imaging, 450*
131I, 99mTc microaggregated albumin, 453*
131I-In-Fe colloid, preparation and imaging, 597
preparation of 131I-In colloid in closed system, 318*
quantitative function with 131I-In colloid, 409*
  RBC morphology and electrophoretic mobility, 391*
  sequestration of RBC, whole-body scanning with 77mFe, 469
Stereoelectrophotography
  brain and thyroid, 326*
Strontium-85
  bone scan interference by oral barium, 145
  bone scanning, comparison with 99mTc, 7Ca, 85Sr and 7Ga, 8
bone scanning for metastatic carcinoma, 429*
  comparison with 85Sr bone scanning, 491
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
  osteoarthrosis of the knee, 109
  spondylitis, comparison of analytic procedures, 213
Strontium-87m
  bone scanning, comparison with 99mTc, 7Ca, 85Sr and 7Ga, 8
  comparison with 85Sr bone scanning, 491
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
Strontium-90
  decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet #4
Sulfur-33
  methionine, post-irradiation protein synthesis in liver, in rats, 351*
  protein free plasma, liquifluor solution for counting, 263
  35SO sala determination in plasma urine, 284
  water space studies following cardiac surgery, 407*
Sulfur colloid
  see Technetium-99m, sulfur colloid
T-4
  see Thyroxine
Table
  low cost, for scanning, 709
Technetium-99m
  aerosol, inhalation scanning, 427*
albumin, distribution and dosimetry in pregnancy, 224
SUBJECT INDEX

albumin, "kit" for sterile labeling, 328*
albumin labeling, 454*
albumin, sub-phrenic abscess, 448*
albumin macroaggregates, kit, 342*
alumin macroaggregates, lung scanning, 394*
alumina macroaggregates, lung scintigraphy, 374*
alumina macroaggregates, thrombophlebitis, 377*
alumina microaggregates, breather artifacts, elimination in liver scanning, 435*
alumina microaggregates, kit, 342*
alumina microaggregates, RES function and scanning, 454*
alumina microspheres, kit, 368*
alumina microspheres, lung imaging, 432*
alumina microspheres, transpulmonary shunting, 344*
cisternography with labeled agents in monkeys, 321*
collimator selection for scintillation camera brain imaging, 297
decay scheme, nuclear parameters, radiation dose, MIRD Pamphlet, 5.4
detection of "Mo in milk, 517
dioxide, liver scanning, 346*
DTPA, autoradiography. rabbit kidney, 362*
elution of "Mo-"Tc generator, 461*, 550
gamma radiation absorption by skull in brain imaging, 184*
hand radiation exposure, 423*, 732
iron colloid for bone marrow imaging, in rabbits, 56, 737
iron hydroxide macroaggregates, preparation and lung scintigraphy, 683
labeling method using Na borohydride, 443*
lung imaging with macroaggregated thionin, 117, 454*
lung, preparation of Tc-S-HSA, 621
point source for transmission imaging, 252, 439*
preparation of metabolizable labeled micropheres, 373*
TcS
macrococaggregates, lung imaging in animals, 402*

Technetium-99m, pertechnetate
bone joint scintigraphy, 356*
brain blood flow, with autofluoroscope, 501
brain blood flow, in CVA, 355*, 401*, 438*
brain blood flow with scintillation camera, 324*, 339*,
355*, 358*, 401*, 438*, 443*
brain imaging, compared to "In-chelates, 18, 290
brain, optimal dose-to-scan interval, 34
brain scanning, arteriovenous malformations, 413*
brain scanning, delayed, 425*
brain scanning, effect of tantalum skull plate, 140
brain scanning, optimizing with Dynapix, 456*
brain scanning, subdural hematoma, 322*
brain scanning, tissue vascularity, 533
cardiac blood flow, 270*
cardiac blood flow, mitral valve disease, 357*
cardiac blood flow, pericardial effusion, 233
cardiac blood flow, R to L shunts, 344*
cardiac blood flow, ventricular and aortic disease, 351°
central circulation dynamics, in children, 338*
chest scanning in pneumonia, 424*
choroid plexus, echoencephalography, 403*
compressive heart disorders, 373*
 coronary blood flow, in dogs, 323*
dual-channel scanning with 3-Se-selenomethionine, 155
gastric secretion, 367*
hydrocephalus, treatment, 322*
identification of gamma rays originating external to skull, 740
pancreas angiography, in dogs, 389*
perchlorate effect on compartmental distribution, 350*, 424*
pericardial effusion diagnosis, 430*
placenta, scanning with 10-crystal detector, 449*
post-irradiation bone marrow blood flow, in rabbits, 361*
salivary glands, scanning, 334*
scalp and skull content, 177
spinal tumor detection, 508
thoracic scintigraphy, 332*
thyroid blocking agents, an evaluation, 462*
thyroid clearance, effect of perchlorate, 637
thyroid imaging, 451*
thyroid trapping function, 421*
thyroid uptake, extrathyroidal neck activity, 483
transmission scanning, lung, 381*
take in brain tumor cell cultures, 349*
yields from generators, 456*

Technetium-99m, sulfur colloid
acid reduction, preparation and distribution, 319*
bone marrow cell function, post-radiation, 361*
bone marrow imaging for radiation damage, 320*
bone marrow imaging, in thalassemia, in children, 351*
H2S preparation, RES scanning, 319*, 386*
liver imaging, 420*, 421*, 628
liver imaging, autofluoroscope, 439*
liver imaging, false-positives, 334*
liver pliability, 416*
liver scanning, children with removed extrabhepatic can-
cers, 433*
liver scanning, comparison with "Au, 391*
liver scanning, elimination of breathing artifacts, 435*
liver scanning, report of 1,000 cases, 327*
liver scintigraphy, cyst-tumor differentiation, 319*
lung-node system visualization, in rabbits, 390*
quality control, Millipore filtration, 399*
stability and autoclaving, 395*
stabilized with HSA, 294, 461*
stabilized with mannotol, 607
sub-phrenic abscess, 448*

Technologist
establishing a good relationship with the patient, 458*

Television
point to point, aid to service in remote areas, 380*
1111T label, distribution, in cats, 697

Therapy
1-chloroquine, malignant melanoma, in dogs, 354*
1I, hyperthyroidism, in children, followup, 586
1I, large initial dose, 341*
1I, progressive malignant exophthalmos, 390*
1I, thyroid carcinoma, survival, 378*
P or alkylating agents, platelet aggregation in poly-
cythemia, 392*
soft tissue analogs, time-dose effects, 398*

Thiamine
deficiency test, in rats, 362*

Thionin
""Tc labeled macroaggregates, lung imaging, 454*

Thorax
scintigraphy, acute mediastinal obstruction, 332*

Three dimensional imaging
thyroid, data averaging and computer analysis, 393*

Three dimensional scanning
nonfocused collimator channel systems, 391*

Thrombophlebitis
imaging with ""Tc-albumin macroaggregates, 379*

Thymidine
H labeled, proliferative activity of bone marrow cells,
410*
incorporation into DNA, effect of radiation, 624

Thymol blue
indicator for 111In-Fe(OH)3 preparation, 633

Thyroid
diagnostic radiography of "hot" nodule, 1131I and 131I, 691
blocking ""TCO3 uptake, 462*
carcinoma causing thyrotoxicosis, 454*
carcinoma, survival in 131I therapy cases, 378*
comparison of assays, serum thyroxine and PBI, 160
computer interpretation of distribution patterns, 618
131Cs, determination of tumor malignancy, 378*
determination of serum thyroxine, 428*

778
extra-thyroidal neck activity, 52, 483
function with 24 hr uptake, T4 and T3, 405*
I131 and Ge(Li) detector, 136
I123, scanning, effect of I131 contamination, 457*
I123 and IRe, in rats, 359*
I131 and I125TcO4, imaging, 451*
I131 therapy, followup on children, 586
I131 uptake, digital computer estimation from scintiscan
matrices, 258
I131 uptake, diuretic augmentation, 340*
I131 uptake, 286
lateral scanning view, 5-in. focus collimator, 459*
minimum activity I131 required for uptake, 475
normal growth rate, 372*
propanol and I123I treatment, 403*
pyramidal thyroid lobe, 519
radioimmunoassay of thyrotropin, 356*
Se-seleomethionine concentration in cold nodules, 452*
serum thyroxine assay, 565
stereoscinophotography, 326*
S252TcO4 clearsance, effect of perchlorate, 637
thyrotoxic crisis treated by plasmapheresis, 319*
thyrotropin and I131 uptake in Graves' disease, 246
trapping function, 421*
uptake, effect of I131 capsule count variations, 461*
whole body I131 retention, quantitative function, 459*
Thyroid hormones
I131 labeled for chest scanning in pneumonia, 424*
Thyroid scanning
computer analysis and data averaging, 393*
Thyrotoxicosis
propanol and I131 treatment, 403*
Thyrotropin
effect on I131 uptake in Graves' disease, 246
radioimmunoassay, 356*
Thyroxine
analysis of thyroxine binding proteins, 532
binding capacity of serum, effect of coumadin, 511
chromatographic separation, 722
comparison radioisotope and column chromatography
assay methods, 281
determination in serum, 428*, 565
direct determination by isotope exchange, 374*
serum thyroxine assay compared with PBI, 160
Tin-113
hematoporphyrin for lymphatic irradiation, 333*
α-Tocopherol
metabolism during vitamin-E deficiency, 441*
Toluidine blue
I131 labeled, distribution in rat, 386*
potential for imaging myocardial infarcts, 413*
Tomography
I13C-carboxylic acids for imaging, 382*
comparison with scintiphography, 356*
eight-detector mapping system, 363*
method evaluation, 358*
scintillation camera, theoretical considerations, 654
Toxicology
long term effects of In administration, 447*
Training
master's program in radiopharmacy, 383*
Transferrin
αFe and I111In labeled, kinetics in pregnant rats, 338*
Transmission
camera and rectilinear scanning, lung, 381*
imaging, positioning for cerebral blood flow, 708
rectilinear scanning for bone mineral content, 379*
rectilinear scanning, I125Tc point source, 252
Transport
transcapillary, labeled proteins, 442*
Tritium
decay scheme, nuclear parameters, radiation dose, MIRD
pamphlet 4
mannotol for GFR, 411*
metabolism of selenium and α-tocopherol, 441*
residual Na in chronic obstructive pulmonary disease, 444*
thymidine, proliferative activity of bone marrow cells, 410*
water space studies following cardiac surgery, 407*
Tryptophane
C13- and I131I labeled, distribution, 342*
Tumor
brain sarcoma, effect of perchlorate on I125I concentration, 350*
growth, 73Se-seleomethionine and 75Rb Cl, 440*
in localization, in rats, 343*
scanning with 99Ga-citrate, 103, 332*
spinal, with I125I, 508
uptake of I131-β-glycerophosphate, in rats, 318*
T-3
chromatographic separation, 722
effect of coumadin, 511
Ultracentrifuge
colloid particle sizing, 387*
Ultrasound
kidney mass differentiation, combined with scintiphography, 367*
periarterial effusion, 125I-MAA and 131I-HSA imaging, 429*
Uptake
C13-cholesterol in adrenal cortex, in dogs, 387*
empirical quantitative measurement from scans, 265
Ga in soft tissue tumors, 406*
I131 effect of thyrotropin in Graves' disease, 246
I131 thyrotropin, digital computer estimation from scintiscan
matrices, 258
minimum activity I131 required for thyroid study, 475
Sb, distribution and retention, in mice, 436*
Se-seleomethionine, in man, 709
thyroid, effect of I131 capsule count variations, 461*
Zn in prostate, 336*
Vitamin B12
deficiency, oxidation of beta-carbon of serine, 329*
Schilling test and plasma level, 457*
uptake measured with whole-body counter, 431*
Vitamin E
metabolism of Se and α-tocopherol, 441*
Whole body
neutron activation analysis for calcium, 360*
potassium, normal ranges, 365*
 Whole-body counting
Cu, gastrointestinal absorption, 591
Cu turnover, Wilson's disease, 451*
I131 retention as a measure of thyroid function, 459*
K and 85Cs, 4* liquid-scintillation, 426*
K in hypertension, 427*
Mn absorption and retention in hemochromatosis, 402*
potassium concentration and Rb metabolism, 1
scatter-window method, 335*
vitamin B12 uptake, 431*
Whole-body scanning
Fe, distribution, 469
Wilson's disease
total body turnover of Cu, 451*
Xenon-133
cerebral blood flow, eight- and sixteen-detector scanners, 164
cisternography, in monkeys, 321*
gamma radiation absorption by skull in brain imaging, 184
inhaled pulmonary function, 345*
liver blood flow, in dog, 330*
myocardial blood flow, 412*
ocular blood flow, 333*
renal blood flow by autoradiography, in rabbits, 362*
SUBJECT INDEX

ventilation and perfusion, 324*, 355*, 412*, 418*, 420*, 428*
ventilation studies with scintillation camera, 374*
X-radiation
effect on mouse fetus, 68
lipid-protein ratios, in vitro tissue, 366*
radiation-protection of leukocytes by cysteamine, 495
Ytterbium-169
brain scanning with DTPA complex, 335*

THE SOCIETY OF NUCLEAR MEDICINE
17th ANNUAL MEETING
July 6–12, 1970
Sheraton Park Hotel
Washington, D.C.

ANNOUNCEMENT AND CALL FOR ABSTRACTS FOR SCIENTIFIC PROGRAM

The Scientific Program Committee welcomes the submission of abstracts of original contributions in nuclear medicine from members and nonmembers of the Society of Nuclear Medicine. Papers will be considered on the following subjects:

- Clinical Diagnosis
- Clinical Investigation
- Radiation Biology
- Radiopharmaceuticals
- Radioisotope Therapy
- Nuclear Instrumentation
- Basic Science Aspects of Nuclear Medicine

Papers will be selected for presentation at plenary sessions as well as at scientific section meetings. In addition, there will be a few papers selected for brief works-in-progress reports. The deadline for receipt of these will be announced at a later date. All regular abstracts must be postmarked no later than February 15, 1970.

GUIDELINES FOR SUBMITTING ABSTRACTS:

Abstracts must be submitted in the following format to receive consideration. Abstracts are to be typed on the official abstract form which can be obtained from a member of the Society or by writing The Society of Nuclear Medicine, 211 East 43rd Street, New York, New York 10017. Five copies must be submitted.

Each abstract must contain the name(s) of the author(s), the institution(s) and the mailing address of the author presenting the paper. Underline the name of the author who will present the paper.

Each abstract must contain the following information in this order:
1. Purpose of the study
2. Methods used
3. Results with pertinent supporting data

Abstracts that are accepted will be published in the June 1970 issue of The Journal of Nuclear Medicine.

So that each work will receive maximum consideration, authors are urged to submit to the Scientific Program Committee supplementary data (charts, graphs, figures, tables, etc.) supporting their abstracts. This material will not be published.

Send the official abstract form and the five copies to:
E. James Potchen, M.D.
Chairman, Scientific Program Committee
Mallinckrodt Institute of Radiology
Washington University School of Medicine
St. Louis, Missouri 63110

DEADLINE: February 15, 1970